Baseline characteristics at the moment of start of mycophenolate mofetil induction treatment in 32 patients with active anti-neutrophil cytoplasmic antibody-associated vasculitis.
| Median (range) or n (%) | |
|---|---|
| ANCA, anti-neutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CRP, C reactive protein; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; WG Wegener’s granulomatosis. | |
| Age (years) | 52 (23–81) |
| Men/women | 16/16 |
| WG/MPA | 29/3 |
| ANCA PR3/MPO/negative | 27/3/2 |
| Duration of disease (years) | 6.0 (0–21.6) |
| Previous relapses | 4 (0–14) |
| Interval between previous and current relapse (months) | 17 (3–134) |
| BVAS | 14 (5–29) |
| CRP (normal <10 mg/l) | 39 (1–361) |
| Creatinine (normal <125 μmol/l) | 106 (73–542) |
| Organ involved | |
| Nose | 23 (72) |
| Eye | 9 (28) |
| Airway/lung | 14 (44) |
| Kidney | 15 (47) |
| Nervous system | 5 (16) |
| Musculoskeletal | 20 (63) |
| Skin | 7 (22) |